$ARSN Mission Statement
Our new mission emerges from
$ARSN Mission Statement
Our new mission emerges from experience and good taste – “Expand the value of assets by putting them to their exciting best use. We rescue assets from the ordinary by infusing them with bold new thinking, extraordinary work and terrific new partnerships. We add value to everything we do.”
Delicious food products and more.
Consider all my posts my opinion and not advice to buy or sell anything. I post on stocks I own or am considering owning. Do your own DD!
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Fractal’s Revenue Moment: Climbing New Peaks Fractal Analytics just knocked it out of the park, folks. Imagine this—an AI company pulling in $100 million for the first quarter, getting a 20% jump in revenue year on year. That's right, these numbers aren't just fancy figures; they're staggering proof that Fractal's hitting its AI stride. The healthcare and life...
Continue Reading
Micropos Medical's Bold Steps into Radiotherapy Let's put a spotlight on a niche that's crying for attention: Micropos Medical is making waves in how we treat prostate cancer. They're leveraging technology with their Raypilot System, and they're partnering with the big guns at Johns Hopkins Medicine. Think about it — five patients in the U.S. are already seeing how this...
Continue Reading
Election Day Drama: Metals Market Jitters You'd think with all the election day hoopla, the metal futures would hold steady. But here we are, seeing gold, silver, and copper futures retracting like a scared turtle. Monday, they all roared upward. Tuesday morning, they're backpedaling. December gold futures took a hit, dropping 0.78% to land at $3,938.50 an ounce. Silver...
Continue Reading
Riding the Kaolin Wave: Industrial Market Expansion You can't miss the sound of kaolin clinking in as it rides the tide of industrial demand. Reports from MarketsandMarkets™ have kaolin's party rocking all the way to a hefty $8.89 billion by 2031, up from $6.19 billion in 2026. With a sensible 7.5% compound annual growth rate (CAGR), this clay’s is aiming for the...
Continue Reading
New Leadership at PASCO scientific Here's the scoop: PASCO scientific is shaking things up at the top by welcoming David Lopez into the CEO chair as of October 5, 2026. Lopez comes packing over two decades of experience in education and organizational leadership. He's stepping into a legacy that's all about making science hands-on and exciting for students—not just in...
Continue Reading
Scage Future Drives Change with NCMCC Partnership Ever hear a platoon of autonomous trucks gearing up, ready to redefine the mining sector? That's exactly what’s brewing between Scage Future and China Huaye Group Co., Ltd. (NCMCC) from the latest update right out of Nanjing. Breaking Down the Deal They've slapped their signature on a non-binding agreement as of...
Continue Reading
A New Player in Dallas-Fort Worth SecureSpace Self Storage has stormed into the Dallas-Fort Worth area, ushering in a sizeable expansion with four brand-new locations. This move is big news for the self-storage operator, marking its very first foray into the Texan market and boosting its nationwide presence past that century mark – 101 stores and counting. Call it a...
Continue Reading
Every now and then, something stirs the soul in a way that neither Wall Street nor Main Street quite can. The 14th annual 'Heroes Meet Heroes' event by WeSalute is poised to do just that. Celebrating Service Through Shared Experiences WeSalute has been a cornerstone for veteran recognition for over two decades, fostering a sense of unity between military service members...
Continue Reading
Budget Pains for Silvercorp's El Domo Project Folks, if you thought navigating the stock market was a minefield, try mining these days. Silvercorp Metals Inc. had to bump up its budget for the El Domo project in Ecuador—again. This time by $14.6 million. What's causing this fiscal heartache? Everything from rising diesel prices thanks to Ecuador playing games with...
Continue Reading
Bright Minds Biosciences Under the Microscope Well, it looks like Bright Minds Biosciences has found itself in some hot water with investors. After the FDA put a partial hold on their Phase 2 trial for BMB-101, designed for epilepsy treatment, the stock took a nosedive. If you're holding a piece of NASDAQ:DRUG, or even if you cut your losses and ran, it's time to tune in....
Continue Reading
Top 5 Most Recently Viewed Articles
SEATOM's Selection for NATO's Accelerator Programme Today, SEATOM announced a significant milestone as it was chosen to participate in the NATO Defence Innovation Accelerator for the North Atlantic (DIANA) 2026 Challenge Programme. This prestigious selection underscores SEATOM's innovative approach to developing nuclear technology tailored for maritime and extreme...
Continue Reading
OpenAI Completes a Major Acquisition OpenAI has recently wrapped up a remarkable deal by acquiring Jony Ive's AI hardware startup, io Products, for a staggering $6.5 billion. This acquisition brings the design genius, renowned for his work at a major tech giant, into OpenAI's fold to help create a new generation of smart devices. Key Developments Post-Acquisition The...
Continue Reading
Opportunities for KinderCare Investors Robbins Geller Rudman & Dowd LLP has announced a significant opportunity for investors of KinderCare Learning Companies, Inc. (NYSE: KLC) who have experienced substantial losses. This is a pivotal moment for shareholders as they can now seek to lead a class action lawsuit against the company. Understanding the Class Action Lawsuit...
Continue Reading
Growth of Baltic Horizon Fund's NAV in May 2025 The Baltic Horizon Fund reported an increase in its net asset value (NAV) per unit, which rose to EUR 0.6757 at the close of May 2025. This figure represents a slight gain from the NAV of EUR 0.6740 recorded at the end of April 2025. The fund's overall net asset value reached EUR 97.0 million, up from EUR 96.8 million in the...
Continue Reading
Autolus Therapeutics Showcases CARLYSLE Trial Results Autolus Therapeutics plc (Nasdaq: AUTL), a biopharmaceutical leader in developing innovative T cell therapies, recently showcased promising preliminary data from the CARLYSLE trial, which focuses on severe refractory systemic lupus erythematosus (srSLE). The data were presented during a special session at a leading...
Continue Reading